NASDAQ:XGN

Exagen (XGN) Stock Price, News & Analysis

Exagen logo
$3.76 -0.01 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$3.76 +0.01 (+0.13%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Exagen Stock (NASDAQ:XGN)

Advanced

Key Stats

Today's Range
$3.64
▼
$3.91
50-Day Range
$3.77
▼
$8.74
52-Week Range
$2.59
▼
$9.22
Volume
1.33 million shs
Average Volume
426,081 shs
Market Capitalization
$95.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.88
Consensus Rating
Moderate Buy

Company Overview

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases.

The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Exagen is based in Vista, California, and serves healthcare providers and patients in the United States. Its business centers on laboratory testing and related diagnostic services for autoimmune disease.

AI Generated. May Contain Errors.

Exagen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

XGN MarketRank™: 
4.060140415945 of 5 stars

Exagen scored higher than 81% of companies evaluated by MarketBeat, and ranked 81st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Exagen has a consensus price target of $9.88, representing about 165.4% upside from its current price of $3.72.

  • Amount of Analyst Coverage

    Exagen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Exagen's stock forecast and price target.
  • Earnings Growth

    Earnings for Exagen are expected to grow in the coming year, from ($0.71) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exagen is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exagen is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exagen has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.35% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 1.98, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exagen has recently increased by 7.96%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Exagen does not currently pay a dividend.

  • Dividend Growth

    Exagen does not have a long track record of dividend growth.

  • News Sentiment

    Exagen has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 36 news articles for Exagen this week, compared to 3 articles on an average week.
  • Search Interest

    9 people have searched for XGN on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exagen insiders have sold 90.77% more of their company's stock than they have bought. Specifically, they have bought $568,660.00 in company stock and sold $1,084,856.00 in company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exagen's insider trading history.
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XGN Stock News Headlines

Exagen (NASDAQ:XGN) Major Shareholder Sells $236,917.44 in Stock
Exagen (NASDAQ:XGN) Major Shareholder Acquires $372,977.45 in Stock
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
Exagen Earnings Call Highlights Growth and Platform Expansion
Exagen (NASDAQ:XGN) Stock Gets Price Target Trim from Canaccord Genuity Group
See More Headlines

XGN Stock Analysis - Frequently Asked Questions

Exagen's stock was trading at $6.08 at the start of the year. Since then, XGN stock has decreased by 38.8% and is now trading at $3.7210.

Exagen Inc. (NASDAQ:XGN) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.07. The company had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.34 million. Exagen had a negative net margin of 25.14% and a negative trailing twelve-month return on equity of 125.60%.
Read the conference call transcript
.

Exagen (XGN) raised $54 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,600,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

Top institutional investors of Exagen include Mink Brook Asset Management LLC (2.08%), First Eagle Investment Management LLC (2.13%), Marshall Wace LLP (1.54%) and Flputnam Investment Management Co. (1.18%). Insiders that own company stock include Nmsic Co-Investment Fund, LP, John Aballi, John Aballi and Kamal Adawi.
View institutional ownership trends
.

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Alibaba Group (BABA), Snap (SNAP), Advanced Micro Devices (AMD), Amneal Pharmaceuticals (AMRX) and Accuray (ARAY).

Company Calendar

Last Earnings
11/10/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:XGN
CIK
1274737
Fax
N/A
Employees
220
Year Founded
2002

Price Target and Rating

High Price Target
$12.00
Low Price Target
$8.00
Potential Upside/Downside
+162.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.95 million
Net Margins
-25.14%
Pretax Margin
-25.07%
Return on Equity
-125.60%
Return on Assets
-33.46%

Debt

Debt-to-Equity Ratio
1.73
Current Ratio
3.46
Quick Ratio
3.18

Sales & Book Value

Annual Sales
$66.57 million
Price / Sales
1.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
6.96

Miscellaneous

Outstanding Shares
25,510,000
Free Float
22,860,000
Market Cap
$95.92 million
Optionable
Optionable
Beta
2.25

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:XGN) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners